Vision Loss (NAION) from GLP-1 Medications in New Hampshire
Last Updated: April 1, 2026
Vision Loss (NAION) cases linked to GLP-1 medications are being filed by New Hampshire residents. New Hampshire's three-year statute of limitations for personal injury and product liability claims provides a moderate filing window for Depo-Provera and GLP-1 medication injury cases. The state's small but densely settled southern region near the Massachusetts border is home to most of its 1.4 million residents, while northern New Hampshire's rural character can delay injury detection. The discovery rule offers critical protection for patients whose pharmaceutical injuries develop gradually over time.
Vision Loss (NAION) has been linked to GLP-1 medications including Ozempic, Wegovy, Mounjaro, Rybelsus. New Hampshire residents who developed vision loss (naion) after using these drugs may qualify for compensation. The product liability statute of limitations in New Hampshire is 3 years. Cases are pending in federal MDL, and attorneys handle claims on a contingency fee basis — no cost unless you win.
Vision Loss (NAION) and GLP-1 Medications
Non-arteritic anterior ischemic optic neuropathy (NAION) is a serious eye condition that causes sudden, painless vision loss — typically in one eye — due to restricted blood flow to the optic nerve. New Hampshire residents who experienced sudden vision changes after taking GLP-1 medications like Ozempic, Wegovy, Mounjaro, Rybelsus may have developed NAION. Research published in JAMA Ophthalmology has identified a statistically significant association between semaglutide use and NAION. The vision loss is often permanent and irreversible, fundamentally altering the patient's ability to drive, read, work, and perform daily activities.
The manufacturers of these medications — Novo Nordisk (maker of Ozempic, Wegovy, and Rybelsus) and Eli Lilly (maker of Mounjaro and Trulicity) — are accused of failing to adequately warn patients and prescribing physicians about the risk of vision loss (naion). Despite internal data and emerging clinical evidence suggesting a causal link, the drug labels did not include sufficient warnings about the severity and potential permanence of this condition.
For New Hampshire residents, this means that if you developed vision loss (naion) while taking a GLP-1 medication, you may have a valid product liability claim. The federal multidistrict litigation (MDL 3094) is consolidating these cases for efficient pretrial proceedings, while preserving each plaintiff's individual right to trial.
Recognizing Vision Loss (NAION) from GLP-1 Drugs
If you are a New Hampshire resident who used Ozempic, Wegovy, Mounjaro, or Rybelsus and experienced any of the following symptoms, you may have developed vision loss (naion) as a result:
Sudden vision loss in one eye
Blurred or dimmed vision
Loss of peripheral vision
Difficulty reading or driving
Diagnosis
Vision Loss (NAION) is typically confirmed through ophthalmologic examination with visual field testing. If you are experiencing symptoms but have not yet received a formal diagnosis, an attorney can help coordinate appropriate medical evaluation as part of your case. Having documented medical evidence strengthens your claim significantly.
Filing a Vision Loss (NAION) Claim in New Hampshire
New Hampshire residents who developed vision loss (naion) after using GLP-1 medications have specific legal options and deadlines. The statute of limitations for product liability claims in New Hampshire is 3 years, and the personal injury statute of limitations is 3 years.
Importantly, New Hampshire recognizes the discovery rule. This means the statute of limitations clock may not start until you knew or reasonably should have known that your vision loss (naion) was caused by a GLP-1 medication. Given that the scientific understanding of the link between these drugs and vision loss (naion) has evolved significantly in recent years, many New Hampshire residents may still be within their filing window even if their injury occurred some time ago.
Cases may be filed in the New Hampshire Superior Courts at the state level or in federal court through the District of New Hampshire. Most GLP-1 injury cases are being coordinated through the federal MDL for pretrial proceedings.
New Hampshire legal landscape: New Hampshire applies modified comparative fault with a 50% bar and follows strict liability for defective products under RSA 507-D, the state's Product Liability Act. The state does not impose statutory caps on compensatory or punitive damages in pharmaceutical cases. Residents in Manchester, Nashua, and Concord and surrounding areas should consult with an attorney to evaluate their potential vision loss (naion) claim.
Personal Injury SOL
3 years
Product Liability SOL
3 years
Discovery Rule
Yes
GLP-1 Drugs Linked to Vision Loss (NAION)
The following GLP-1 receptor agonist medications have been linked to vision loss (naion) in ongoing litigation. If you used any of these drugs in New Hampshire and developed vision loss (naion), you may qualify for a claim:
Ozempic
Semaglutide injection by Novo Nordisk. Prescribed for type 2 diabetes.
Wegovy
Semaglutide injection by Novo Nordisk. Prescribed for weight management.
Mounjaro
Tirzepatide injection by Eli Lilly. Prescribed for type 2 diabetes and weight management.
Rybelsus
Oral semaglutide by Novo Nordisk. Prescribed for type 2 diabetes.
Do You Qualify for a Vision Loss (NAION) Claim in New Hampshire?
New Hampshire residents may be eligible to file a vision loss (naion) claim if the following criteria apply:
Used a GLP-1 Medication
You were prescribed and used Ozempic, Wegovy, Mounjaro, or Rybelsus or another GLP-1 receptor agonist medication.
Diagnosed with Vision Loss (NAION)
You received a medical diagnosis of vision loss (naion) through ophthalmologic examination with visual field testing.
Injury Occurred After Drug Use
Your vision loss (naion) developed after you began taking the GLP-1 medication, establishing a timeline consistent with causation.
Within New Hampshire's Filing Deadline
Your claim falls within New Hampshire's product liability statute of limitations (3 years). The discovery rule may extend this deadline. An attorney can evaluate your specific timeline.
Vision Loss (NAION) in New Hampshire: FAQ
What is vision loss (naion) and how is it linked to GLP-1 medications in New Hampshire?
Non-arteritic anterior ischemic optic neuropathy causing sudden, painless vision loss. GLP-1 medications including Ozempic, Wegovy, Mounjaro, Rybelsus have been linked to an increased risk of developing this condition. New Hampshire residents who were prescribed these medications and subsequently developed vision loss (naion) may be eligible to file a lawsuit seeking compensation for their injuries, medical expenses, and other damages.
What are the symptoms of vision loss (naion) caused by Ozempic or other GLP-1 drugs?
Common symptoms of vision loss (naion) include sudden vision loss in one eye, blurred or dimmed vision, loss of peripheral vision, difficulty reading or driving. If you experienced these symptoms after taking Ozempic, Wegovy, Mounjaro, or Rybelsus in New Hampshire, you should seek medical attention immediately and consider having your case evaluated for potential legal action.
How is vision loss (naion) diagnosed for purposes of a GLP-1 lawsuit?
Vision Loss (NAION) is typically diagnosed through ophthalmologic examination with visual field testing. For New Hampshire residents filing a GLP-1 injury claim, medical documentation confirming your diagnosis is important for establishing your case. If you have not yet been formally diagnosed but are experiencing symptoms, your attorney can help coordinate appropriate medical evaluation.
What is the statute of limitations for a vision loss (naion) claim in New Hampshire?
In New Hampshire, the statute of limitations for product liability claims is 3 years. New Hampshire recognizes the discovery rule, meaning the filing deadline may start from when you discovered or should have discovered that your vision loss (naion) was caused by a GLP-1 medication. Consult with an attorney to determine your exact deadline.
What compensation can I receive for vision loss (naion) caused by GLP-1 drugs in New Hampshire?
New Hampshire residents who qualify may recover compensation for medical expenses (including ophthalmologic care, assistive devices, and rehabilitation), lost wages, pain and suffering, emotional distress, and diminished quality of life. The amount depends on the severity of your vision loss (naion) and its impact on your daily life.
Is there any cost to file a vision loss (naion) claim in New Hampshire?
There is no upfront cost. Attorneys handling GLP-1 vision loss (naion) cases in New Hampshire work on a contingency fee basis, meaning they only receive payment if you receive compensation through settlement or trial verdict. NuLegal's initial case review is completely free with no obligation.
Other GLP-1 Injuries in New Hampshire
New Hampshire Residents: Get Your Free Case Review
If you developed vision loss (naion) after using Ozempic, Wegovy, Mounjaro, or Rybelsus, time may be limited. New Hampshire's product liability statute of limitations is 3 years. Get a free, no-obligation evaluation today.
Free Case ReviewAdvertisement
Disclosure: NuLegal operates as a legal referral service. Attorney Ashkaan Hassan evaluates claims and refers qualified cases to specialized trial firms, earning a referral fee from the attorney's share of any recovery. Clients never pay out of pocket.